埃佩里松化是一种肌肉放松剂,是一种强大的P2X7受体对手
1ASKA Pharmaceutical Co., Ltd., Research Management Department.
Chemical & pharmaceutical bulletin
|March 31, 2024
概括
用于肌肉强度的埃佩里松化被发现向P2X7受体. 这一发现揭示了一种新的作用机制,并暗示了Eperisone化的潜在药物重新定位.
科学领域:
- 药理学 药理学是指药理学的学科.
- 神经科学是一个神经科学.
- 药物发现 药物发现 药物发现
背景情况:
- 埃佩里松化,自1983年以来,可用于治疗肌肉和性.
- 埃佩里松化的精确生化机制仍然没有被阐明.
- 纯能P2X受体与各种生理和病理过程有关.
研究的目的:
- 为了阐明Eperisone化的生化作用机制.
- 为了确定Eperisone化的特定分子标.
- 探索Eperisone化在药物重新定位方面的潜力.
主要方法:
- 利用SB药物发现平台进行高通量查.
- 采用基于光的测试来评估纯能P2X受体对抗性.
- 研究了Eperisone化与特定的P2X受体亚型的相互作用.
主要成果:
- 确定了P2X7受体作为Eperisone化的主要分子标.
- 对于Eperisone化对P2X受体的对抗作用,已显示出高的亚型选择性.
- 建立了Eperisone化,P2X7受体和疼痛通路之间的直接联系.
结论:
- 埃佩里松化作为P2X7受体对抗剂.
- 验证了P2X7受体作为治疗干预的可行的药物标.
- 埃佩里松化在涉及P2X7受体活性的条件下为药物重新定位提供了一个机会,可能包括疼痛管理.
相关概念视频
Ligand-Gated Ion Channel Receptor: Gating Mechanism
2.2K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
2.2K
Depolarizing Blockers: Mechanism of Action
1.5K
Depolarizing blockers act on skeletal muscle fibers' membranes and induce their depolarization. Most depolarizing blockers have two quaternary N+ atoms that bind the nicotinic acetylcholine receptors and cause neuromuscular blockade within minutes.
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because...
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because...
1.5K
GPCR Desensitization
6.0K
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
6.0K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
159
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
159
Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
1.8K
Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
1.8K
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
806
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
806


